Canadian Cancer Trials Group Bulletins


Canadian Cancer Trials Group MA.20 Results Presented at ASCO

These results were chosen to be included in ASCO's Official Press Program and were highlighted during a press conference on Saturday, June 4. MA.20 was presented by the trial chair, Dr. Tim Whelan from McMaster University in Hamilton, Ontario.

Dr. Whelan's presentation received wide media coverage, including in Time Magazine ( The Canadian Cancer Society has also highlighted these results (, as has the NCI Cancer Bulletin (

Following is the press release issued by ASCO to coincide with Dr. Whelan¿s presentation:

Adding Regional Nodal Irradiation Decreases Recurrences in Women with Early, High-Risk Breast Cancer

Interim analysis data from a randomized Phase III trial showed that, in women with node-positive or high-risk node-negative breast cancer, additional radiation treatment to the regional lymph nodes (regional nodal irradiation, or RNI) improves disease-free survival, reducing cancer recurrences both near the tumour site and in other parts of the body. In addition, overall mortality was reduced by 24 percent in the group receiving RNI, but this did not reach statistical significance.

"These results are potentially practice-changing. They will encourage physicians to offer all women with node-positive disease the option of receiving regional nodal irradiation," said Dr. Timothy J. Whelan, BM BCh, lead study investigator for the Canadian Cancer Trials Group and a Professor of Oncology and Division Head of Radiation Oncology at McMaster University and the Juravinski Cancer Centre, Hamilton, Ontario. "Adding regional nodal irradiation improved disease-free survival, lowered the risk of recurrences, and there was a positive trend toward improved overall survival, while not greatly increasing toxicities."

Women with node-positive breast cancer are treated with breast-conserving surgery plus axillary lymph node dissection, followed by radiation to the breast (whole breast irradiation, or WBI). If a woman's cancer has high-risk features, such as a tumour larger than 5 cm or more than three positive axillary nodes, she often receives regional nodal irradiation, or RNI. However, for women with one to three positive nodes, the benefit of adding RNI has been unclear.

The study enrolled 1,832 women, most of whom (85%) had one to three positive lymph nodes , and a smaller proportion of women (10%) who had high-risk, node-negative breast cancer. All women had been treated with breast-conserving surgery and adjuvant chemotherapy or endocrine therapy. The participants were randomized to receive either WBI alone or WBI plus RNI.

A protocol specified interim analysis of the data conducted in March 2011 found that after a median follow up of 62 months, there were statistically significant benefits for the group receiving the added RNI therapy. These included a greater than 30 percent improvement in disease free survival (from 84 percent for those who received WBI to 89.7 percent for those who also got RNI at 5 years), as a result of a 41 percent lower rate of recurrences near the tumour site (from 5.5 percent to 3.2 percent at 5 years), and a 36 percent lower rate of cancer recurrences in other parts of the body (from 13 percent to 7.6 percent at 5 years).

The patients who received the added RNI had a low but statistically significant increased risk of grade 2 or greater pneumonitis and lymphedema.

The Canadian Cancer Trials Group would like to acknowledge programmatic funding support from the Canadian Cancer Society Research Institute. Additionally, MA.20 was supported by the US National Cancer Institute / Cancer Therapy Evaluation Program and liance.

As we reported in the previous edition of the Canadian Cancer Trials Group Bulletin, several abstracts related to Canadian Cancer Trials Group trials or trials which included Canadian Cancer Trials Group participation were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL, June 3-7, 2011, including Canadian Cancer Trials Group-led MA.20, MAP.3, and PR.7 chosen as among the "Best of ASCO."